Clinical Study of Macitentan in Patients With PAH to Psychometrically Validate PAH-SYMPACT Instrument

PHASE3TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 1, 2013

Primary Completion Date

October 1, 2015

Study Completion Date

November 30, 2017

Conditions

Pulmonary Arterial Hypertension

Interventions

DRUG

Macitentan

Macitentan tablet, dose of 10 mg, once daily.

Trial Locations (2)

Kentuckiana Pulmonary Associates, Louisville

The Carl & Edyth Lindner Center for Research & Education at The Christ Hospital, Cincinnati